Pre and post community B | Post community B | p-value pre and post community B vs. post community B | |
---|---|---|---|
Number | 7 | 12 | |
Age [years] | 64.0 (58.5–67.0) | 70.0 (58.5–75.0) | 0.445 |
ASA status | 2.0 (2.0–2.5) | 3.0 (2.0–3.0) | 0.118 |
Cardiovascular risk factors | |||
Coronary heart disease | 0 (0.0%) | 2 (16.7%) | 0.253 |
Diabetes | 2 (28.6%) | 3 (25.0%) | 0.865 |
Arterial hypertension | 2 (28.6%) | 6 (50.0%) | 0.361 |
Chronic renal failure | 0 (0.0%) | 0 (0.0%) | 1.000 |
Primary disease | |||
Malignant | 4 (57.1%) | 9 (75.0%) | 0.419 |
IPMN | 3 (42.9%) | 2 (16.7%) | 0.211 |
Chronic pancreatitis | 0 (0.0%) | 1 (8.3%) | 0.433 |
Operation | |||
Partial pancreaticoduodenectomy | 4 (57.1%) | 3 (25.0%) | 0.161 |
Pylorus-preserving pancreas head resection | 1 (14.3%) | 5 (41.7%) | 0.216 |
Total pancreatectomy | 1 (14.3%) | 0 (0.0%) | 0.179 |
Distal pancreatectomy | 1 (14.3%) | 2 (16.7%) | 0.891 |
Tumour enucleation | 0 (0.0%) | 2 (16.7%) | 0.253 |
Surgery [min] | 330.0 (315.0–360.0) | 240.0 (176.3–333.8) | 0.149 |
Blood loss1 [mL] | 750.0 (600.0–1300.0) | 600.0 (500.0–800.0) | 0.251 |
Infusion1 [mL] | 3000.0 (2750.0–4250.0) | 3000.0 (2375.0–3750.0) | 0.491 |
Transfusion1 [mL] | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 1.000 |
CRP2 [mg/L] | 147.5 (79.2–175.8) | 86.7 (45.5–148.0) | 0.178 |
Leucocytes2 [1/nL] | 12.5 (8.6–14.0) | 10.4 (8.0–12.9) | 0.370 |
Hospital stay | |||
In total [days] | 15.0 (10.5–32.0) | 16.0 (11.8–33.8) | 0.641 |
Intermediate care unit [days] | 0.0 (0.0–5.5) | 0.0 (0.0–0.3) | 0.539 |
Intensive care unit [days] | 1.0 (0.0–1.5) | 0.0 (0.0–1.0) | 0.295 |
Postoperative complications [Clavien-Dindo classification] | |||
Grade I | 3 (42.9%) | 2 (16.7%) | 0.211 |
Grade II | 1 (14.3%) | 5 (41.7%) | 0.363 |
Grade III3 | 0 (0.0%) | 2 (16.7%) | 0.253 |
Grade IV4 | 0 (0.0%) | 0 (0.0%) | 1.000 |
Grade V | 1 (14.3%) | 1 (8.3%) | 0.683 |
Outcome | |||
Survivor 90 days | 13 (100.0%) | 19 (100.0%) | 1.000 |